CMPS Stock Overview
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States.
COMPASS Pathways Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$19.73|
|52 Week High||US$49.52|
|52 Week Low||US$6.54|
|1 Month Change||59.89%|
|3 Month Change||179.46%|
|1 Year Change||-34.58%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-31.97%|
Recent News & Updates
COMPASS Pathways ADS Q2 2022 Earnings Preview
COMPASS Pathways ADS (NASDAQ:CMPS) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is -$0.60 (-36.4% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 5 upward revisions and 0 downward.
|CMPS||US Biotechs||US Market|
Return vs Industry: CMPS underperformed the US Biotechs industry which returned -25.9% over the past year.
Return vs Market: CMPS underperformed the US Market which returned -13.5% over the past year.
|CMPS Average Weekly Movement||11.8%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CMPS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CMPS's weekly volatility (12%) has been stable over the past year.
About the Company
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
COMPASS Pathways Fundamentals Summary
|CMPS fundamental statistics|
Is CMPS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CMPS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.97|
|Net Profit Margin||0.00%|
How did CMPS perform over the long term?See historical performance and comparison
Is CMPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CMPS?
Other financial metrics that can be useful for relative valuation.
|What is CMPS's n/a Ratio?|
Price to Book Ratio vs Peers
How does CMPS's PB Ratio compare to its peers?
|CMPS PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
YMAB Y-mAbs Therapeutics
TGTX TG Therapeutics
TIL Instil Bio
CMPS COMPASS Pathways
Price-To-Book vs Peers: CMPS is good value based on its Price-To-Book Ratio (3.7x) compared to the peer average (4.5x).
Price to Earnings Ratio vs Industry
How does CMPS's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: CMPS is expensive based on its Price-To-Book Ratio (3.7x) compared to the US Biotechs industry average (1.8x)
Price to Book Ratio vs Fair Ratio
What is CMPS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||3.7x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate CMPS's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CMPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CMPS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CMPS's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is COMPASS Pathways forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CMPS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CMPS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CMPS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CMPS is forecast to have no revenue next year.
High Growth Revenue: CMPS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CMPS is forecast to be unprofitable in 3 years.
Discover growth companies
How has COMPASS Pathways performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CMPS is currently unprofitable.
Growing Profit Margin: CMPS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CMPS is unprofitable, and losses have increased over the past 5 years at a rate of 42.4% per year.
Accelerating Growth: Unable to compare CMPS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CMPS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).
Return on Equity
High ROE: CMPS has a negative Return on Equity (-37.27%), as it is currently unprofitable.
Discover strong past performing companies
How is COMPASS Pathways's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CMPS's short term assets ($232.0M) exceed its short term liabilities ($13.2M).
Long Term Liabilities: CMPS's short term assets ($232.0M) exceed its long term liabilities ($818.0K).
Debt to Equity History and Analysis
Debt Level: CMPS is debt free.
Reducing Debt: CMPS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CMPS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CMPS has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 51.5% each year.
Discover healthy companies
What is COMPASS Pathways's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CMPS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CMPS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CMPS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CMPS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CMPS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Kabir Nath M.A., M.B.A., is Chief Executive Officer of COMPASS Pathways plc from August 1, 2022. He serves as President & CEO at Otsuka America Pharmaceutical, Inc. He served as President and Chief Exe...
Experienced Management: CMPS's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: CMPS's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
COMPASS Pathways plc's employee growth, exchange listings and data sources
- Name: COMPASS Pathways plc
- Ticker: CMPS
- Exchange: NasdaqGS
- Founded: 2020
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$838.967m
- Shares outstanding: 42.52m
- Website: https://compasspathways.com
Number of Employees
- COMPASS Pathways plc
- 33 Broadwick Street
- Greater London
- W1F 0DQ
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/08/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.